How does ARAV's PS Ratio compare to its peers?

ARAV is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (22.1x).

How does ARAV's PS Ratio compare vs other companies in the US Biotechs Industry?

ARAV is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Biotechs industry average (13.5x).

What is ARAV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ARAV's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of ARAV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ARAV's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Aravive (Nasdaq:ARAV) - Stock Price, News & Analysis

ARAV Stock Overview

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. More details

ARAV fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Earnings have declined by 12.3% per year over past 5 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months

Does not have a meaningful market cap ($3M)

+ 1 more risk

Aravive, Inc. Competitors

Aditxt

NasdaqCM:ADTX

US$2.8m

Azitra

NYSEAM:AZTR

US$3.6m

Molecular Templates

NasdaqCM:MTEM

US$2.2m

Fresh2 Group

NasdaqCM:FRES

US$2.8m

Price History & Performance

Summary of all time highs, changes and price drops for Aravive
Historical stock prices
Current Share Price	US$0.04
52 Week High	US$2.46
52 Week Low	US$0.04
Beta	2.19
11 Month Change	-67.58%
3 Month Change	-69.30%
1 Year Change	-97.63%
33 Year Change	-99.22%
5 Year Change	-99.06%
Change since IPO	-99.98%

Recent updates

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

Shareholder Returns

	ARAV	US Biotechs	US Market
7D	-17.3%	2.4%	2.2%
1Y	-97.6%	16.2%	31.7%

Return vs Industry: ARAV underperformed the US Biotechs industry which returned 6.5% over the past year.

Return vs Market: ARAV underperformed the US Market which returned 17.6% over the past year.

Price Volatility

Is ARAV's price volatile compared to industry and market?
ARAV volatility
ARAV Average Weekly Movement	19.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ARAV's share price has been volatile over the past 3 months.

Volatility Over Time: ARAV's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2008	23	n/a	aravive.com

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.

Aravive, Inc. Fundamentals Summary

How do Aravive's earnings and revenue compare to its market cap?
ARAV fundamental statistics
Market cap	US$2.95m
Earnings (TTM)	-US$39.85m
Revenue (TTM)	US$6.99m

0.4x

P/S Ratio

-0.1x

P/E Ratio

Is ARAV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARAV income statement (TTM)
Revenue	US$6.99m
Cost of Revenue	US$53.39m
Gross Profit	-US$46.39m
Other Expenses	-US$6.55m
Earnings	-US$39.85m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.54
Gross Margin	-663.34%
Net Profit Margin	-569.73%
Debt/Equity Ratio	0%

How did ARAV perform over the long term?

See historical performance and comparison

ARAV Stock Overview

Risk Analysis

Aravive, Inc. Competitors

NasdaqCM:ADTX

US$2.8m

NYSEAM:AZTR

US$3.6m

NasdaqCM:MTEM

US$2.2m

NasdaqCM:FRES

US$2.8m

Price History & Performance

Recent News & Updates

Aravive Files Form 15

Aravive, Inc. Announces Board and Committee Resignations

Aravive, Inc. Notifies Nasdaq of its Intention to File a Form 25 on or About January 29, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Aravive Receives Letters from Nasdaq Regarding Non-Compliance with Minimum Market Value of its Listed Securities, Minimum Market Value of its Publicly Held Shares, and Minimum Closing Bid Price Requirement

Recent updates

Aravive Files Form 15

Aravive, Inc. Announces Board and Committee Resignations

Aravive, Inc. Notifies Nasdaq of its Intention to File a Form 25 on or About January 29, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Aravive Receives Letters from Nasdaq Regarding Non-Compliance with Minimum Market Value of its Listed Securities, Minimum Market Value of its Publicly Held Shares, and Minimum Closing Bid Price Requirement

Aravive, Inc., Annual General Meeting, Oct 02, 2023

Consensus revenue estimates decrease by 51%

Aravive, Inc. Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer

Consensus revenue estimates increase by 95%

Aravive, Inc. Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 35%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive, Inc. Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian

Aravive Inc. Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 44%

Price target decreased to US$9.80

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Aravive, Inc. announced that it has received $41.559988 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC, and other investors

Consensus forecasts updated

Aravive, Inc. announced that it expects to receive $41.55547 million in funding from BVF Partners L.P., Eshelman Ventures, LLC, The Invus Group, LLC

Consensus forecasts updated

Aravive Receives Third Development Milestone from 3D Medicines

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Consensus revenue estimates increase by 10%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aravive Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Aravive Q2 GAAP EPS misses, revenue beats

Aravive, Inc., Annual General Meeting, Sep 22, 2022

Aravive, Inc. Appoints Robert B. Geller as Chief Medical Officer

Aravive appoints Robert Geller as CMO

Price target decreased to US$18.20

Aravive, Inc. Appoints Rudy Howard as Chief Financial Officer

Aravive, Inc. Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential of Batiraxcept in Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Consensus revenue estimates fall by 25%

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

High number of new directors

Consensus forecasts updated

Price target decreased to US$19.75

Aravive, Inc. Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

Aravive to Present Updated Modeling Data from Batiraxcept Clinical Trials at the AACR Annual Meeting

Aravive, Inc. Announces First Patient Dosed in Phase 2 Study of Batiraxcept in Clear Cell Renal Cell Carcinoma

High number of new directors

Aravive, Inc. announced that it has received $10.000001 million in funding from Eshelman Ventures, LLC

Aravive, Inc. announced that it expects to receive $10.000001 million in funding from Eshelman Ventures, LLC

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive Inc Announces First Patient Dosed in Phase 1B/2 Clinical Trial of AVB-500 for the Treatment of Pancreatic Adenocarcinoma

Consensus revenue estimates increase to US$7.34m

Aravive, Inc.(NasdaqGS:ARAV) dropped from Russell Microcap Growth Index

Aravive Announces Positive Initial Results from Phase 1b Portion of the Phase1b/2 Study of AVB-500

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Consensus revenue estimates increase to US$4.10m

Aravive, Inc. Plans to Investigate AVB-500 in Clinical Trial as First-Line Treatment for Pancreatic Cancer

Aravive EPS beats by $0.01, misses on revenue

Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer

Aravive shares rise after dosing first patient in late-stage ovarian cancer study